United States Patent 7,300,935: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 7,300,935, titled "Thienopyrimidine compounds and use thereof," is a significant patent in the pharmaceutical sector, particularly in the treatment of various diseases. This patent, issued to Takeda Pharmaceutical Company Limited, involves a class of compounds known as thienopyrimidines, which have shown promise in medical treatments.
Patent Overview
Patent Number and Issue Date
The patent number is US 7,300,935 B2, and it was issued on November 20, 2007[4].
Inventors and Assignees
The inventors listed on the patent include Cho Nobuo, Imada Takashi, Hitaka Takenori, Miwa Kazuhiro, Kusuka Masami, and Suzuki Nobuhiro. The assignee is Takeda Pharmaceutical Company Limited[4].
Claims and Scope
Compound Description
The patent describes a class of thienopyrimidine compounds, which are defined by a specific chemical formula. These compounds are characterized by their structure, which includes various substituents such as alkyl groups, nitrogen-containing rings, and other functional groups[4].
Independent Claims
The patent includes multiple independent claims that define the scope of the invention. These claims cover the chemical compounds themselves, their methods of preparation, and their use in therapeutic applications. For example, Claim 1 describes a compound represented by a specific formula, while subsequent claims detail various aspects of the compound's synthesis and application[4].
Dependent Claims
Dependent claims further narrow down the scope by specifying particular embodiments of the invention. These claims often detail specific substituents, dosages, and methods of administration, providing a comprehensive coverage of the invention's various aspects[4].
Patent Expiration Date
The patent is set to expire on January 28, 2025, marking the end of the exclusive rights granted to Takeda Pharmaceutical Company Limited for this specific class of thienopyrimidine compounds[2][4].
Therapeutic Applications
Treatment of Prostate Cancer
One of the significant therapeutic applications of the compounds described in this patent is the treatment of prostate cancer. The patent details the use of these compounds in formulations designed to target and inhibit the growth of cancer cells[2][4].
Other Potential Uses
While the primary focus is on prostate cancer, the thienopyrimidine compounds may also have potential applications in treating other diseases due to their broad pharmacological profiles. This includes anti-inflammatory, antiviral, and antibacterial uses, among others[4].
Patent Landscape
Related Patents
The patent landscape surrounding US 7,300,935 includes several related patents that cover similar or complementary inventions. For example, patents such as US 8,058,280 and US 8,735,401 also relate to thienopyrimidine compounds and their uses, often with overlapping but distinct claims[2][4].
Exclusivity and Regulatory Considerations
In addition to patent protection, the FDA may grant exclusivity periods that run concurrently with or independently of patent protection. For instance, the FDA can grant new chemical entity (NCE) exclusivity, which can extend the exclusive marketing rights beyond the patent expiration date[2].
Impact on Pharmaceutical Industry
Generic Competition
The expiration of this patent in 2025 will open the door for generic competition. Generic manufacturers can file Abbreviated New Drug Applications (ANDAs) referencing the original drug, potentially leading to a significant reduction in prices and increased accessibility of the medication[1][2].
Innovation and Research
The expiration of this patent can also stimulate further innovation and research. With the basic compounds no longer under exclusive protection, other companies may invest in developing new formulations, combinations, or uses for these compounds, driving advancements in medical treatments[3].
Legal and Regulatory Aspects
Patent Scope and Claim Clarity
The scope and clarity of patent claims are critical in defining the boundaries of the invention. Metrics such as independent claim length and independent claim count can be used to measure patent scope, which can impact the patent's validity and enforceability[3].
Litigation and Enforcement
Patents like US 7,300,935 are often subject to litigation and post-grant administrative reviews. The clarity and breadth of the claims can significantly influence the outcome of such proceedings, affecting the patent's lifespan and the rights of the patent holder[3].
Conclusion
United States Patent 7,300,935 represents a significant contribution to the field of pharmaceuticals, particularly in the treatment of prostate cancer. Understanding the scope, claims, and patent landscape of this invention is crucial for both the patent holder and potential competitors. As the patent approaches its expiration date, it is likely to have a profound impact on the pharmaceutical industry, driving competition, innovation, and ultimately benefiting patients.
Key Takeaways
- Patent Number and Issue Date: US 7,300,935 B2, issued on November 20, 2007.
- Inventors and Assignees: Cho Nobuo, Imada Takashi, Hitaka Takenori, Miwa Kazuhiro, Kusuka Masami, and Suzuki Nobuhiro; assigned to Takeda Pharmaceutical Company Limited.
- Claims and Scope: Covers thienopyrimidine compounds, their synthesis, and therapeutic applications.
- Patent Expiration Date: January 28, 2025.
- Therapeutic Applications: Primarily for the treatment of prostate cancer.
- Impact on Industry: Expiration will lead to generic competition and potential innovation in new formulations.
Frequently Asked Questions (FAQs)
What is the main subject of United States Patent 7,300,935?
The main subject is thienopyrimidine compounds and their use in therapeutic applications.
Who are the inventors of this patent?
The inventors include Cho Nobuo, Imada Takashi, Hitaka Takenori, Miwa Kazuhiro, Kusuka Masami, and Suzuki Nobuhiro.
What is the expiration date of this patent?
The patent is set to expire on January 28, 2025.
What are the potential therapeutic applications of the compounds described in this patent?
The primary application is the treatment of prostate cancer, but the compounds may also have other potential uses such as anti-inflammatory, antiviral, and antibacterial treatments.
How will the expiration of this patent affect the pharmaceutical industry?
The expiration will open the market to generic competition, potentially reducing prices and increasing accessibility of the medication, and may also stimulate further innovation and research.
Cited Sources
- GreyB, "Drug Patents Expiring in 2024," GreyB Blog.
- Drugs.com, "Generic Orgovyx Availability," Drugs.com.
- Hoover Institution, "Patent Claims and Patent Scope," Hoover Institution Working Paper Series.
- Google Patents, "US7300935B2 - Thienopyrimidine compounds and use thereof," Google Patents.
- Federal Register, "Determination of Regulatory Review Period for Purposes of Patent Extension - Orgovyx," Federal Register.
